Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

ClinicalTrials.gov ID: NCT02064439

Public ClinicalTrials.gov record NCT02064439. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 4:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism

Study identification

NCT ID: NCT02064439
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bayer; Industry
Enrollment: 3,365 participants

Conditions and interventions

Conditions

Interventions

BAY 59-7939 Drug
ASA Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 4, 2014
Primary completion: Sep 21, 2016
Completion: Nov 3, 2016
Last update posted: Dec 18, 2017

2014 – 2016

United States locations

U.S. sites: 24
U.S. states: 16
U.S. cities: 22

Facility	City	State	ZIP	Site status
Not listed	Beverly Hills	California	90211	—
Not listed	La Jolla	California	92037	—
Not listed	Ventura	California	93003	—
Not listed	Denver	Colorado	80262	—
Not listed	Jacksonville	Florida	32207	—
Not listed	Columbus	Georgia	31904	—
Not listed	Joliet	Illinois	60435	—
Not listed	Rockport	Maine	04856	—
Not listed	Boston	Massachusetts	02114-2696	—
Not listed	Boston	Massachusetts	02115	—
Not listed	Boston	Massachusetts	02215	—
Not listed	Detroit	Michigan	48202	—
Not listed	Butte	Montana	59701	—
Not listed	Las Vegas	Nevada	89169	—
Not listed	Raleigh	North Carolina	27607	—
Not listed	Columbus	Ohio	43210-1240	—
Not listed	Toledo	Ohio	43606	—
Not listed	Philadelphia	Pennsylvania	19104	—
Not listed	San Antonio	Texas	78229	—
Not listed	Fredericksburg	Virginia	22401	—
Not listed	Bellevue	Washington	98004	—
Not listed	Seattle	Washington	98104	—
Not listed	Spokane	Washington	99216	—
Not listed	Tacoma	Washington	98405-2433	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 242 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02064439, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 18, 2017 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02064439 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →